News | Orthopedic Imaging | May 23, 2017

Asterias MRI Data Shows AST-OPC1 Cells Prevent Cavitation in Severe Spinal Cord Injury Patients

Data indicate disease-modifying aspects of AST-OPC1 may carry long-term benefits related to both recovery and maintenance of motor and sensory function

Asterias MRI Data Shows AST-OPC1 Cells Prevent Cavitation in Severe Spinal Cord Injury Patients

May 23, 2017 — Asterias Biotherapeutics Inc. recently announced new positive serial magnetic resonance imaging (MRI) data from its ongoing AST-OPC1 SCiStar Phase 1/2a clinical trial in patients with severe spinal cord injury.

Study data indicated that:

  • For the five AIS-A patients in the SCiStar study treated with 10 million AST-OPC1 cells (Cohort 2) who also received a serial MRI scan at six months of follow-up, the serial MRI scans indicated no sign of lesion cavities in any patient. These fluid-filled cavities typically form by about three months following severe spinal cord injury and prevent significant recovery of motor and sensory function;
  • For the three patients in Cohort 2 that have also completed 12 months of follow-up, serial MRI scans at 12 months continued to indicate no signs of lesion cavities; and
  • All three AIS-A patients who received a low dose of 2 million cells (Cohort 1) in the SCiStar study also showed no sign of lesion cavities in any patient through 1 year of follow-up.  All three patients are continuing long-term follow-up and will receive additional MRI scans annually.

The MRI results are supportive of the extensive pre-clinical data on AST-OPC1 showing that the cells durably engraft and help prevent cavitation at the injury site. Cavitation is a destructive process that occurs within the spinal cord following spinal cord injuries, and typically results in permanent loss of motor and sensory function. Additionally, a patient with cavitation can develop a condition known as syringomyelia, which results in additional neurological and functional damage to the patient.

Under the study protocol, patients are monitored by MRI scans at regular intervals over 12 months in order to assess status of the injection site and surrounding tissues.

For more information: www.asteriasbiotherapeutics.com

Related Content

Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
Ingenia Ambition X 1.5T MR. This innovation is the latest advance in the Ingenia MRI portfolio, which comprises fully-digital MRI systems, healthcare informatics and a range of maintenance and life cycle services for integrated solutions that empower a faster, smarter, and simpler path to enabling a confident diagnosis
News | Magnetic Resonance Imaging (MRI) | September 14, 2018
Philips, a global leader in health technology, launched the Ingenia Ambition X 1.5T MR.
Veye Chest version 2
News | Lung Cancer | September 11, 2018
Aidence, an Amsterdam-based medical AI company, announced that Veye Chest version 2, a class IIa medical device, has
Sponsored Content | Case Study | Magnetic Resonance Imaging (MRI) | September 07, 2018 | By Sabine Sartoretti, M.D.
As soon as the Compressed SENSE technology became available to the MRI team at Kantonsspital Winterthur (Switzerland),...
Mount Sinai Serves as Official Medical Services Provider for 2018 U.S. Open
News | Orthopedic Imaging | September 06, 2018
For the sixth consecutive year, Mount Sinai will serve as the official medical services provider for the 2018 U.S. Open...
Carestream Releases Second-Generation Metal Artifact Reduction Software for OnSight 3D Extremity System
Technology | Computed Tomography (CT) | September 06, 2018
Carestream Health has started shipping a new software version for its Carestream OnSight 3D Extremity System that...

Image courtesy of Philips Healthcare

Feature | Magnetic Resonance Imaging (MRI) | September 06, 2018 | By Melinda Taschetta-Millane
According to the Prescient & Strategic Intelligence report, “Global Magnetic Resonance Imaging (MRI) Market Size,...
Konica Minolta Provides Sonimage HS1 Ultrasound for AAPM&R Hands-on Learning Course
News | Ultrasound Imaging | September 05, 2018
Konica Minolta Healthcare Americas recently provided ultrasound systems for The American Academy for Physical Medicine...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...